SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (604)11/12/2003 12:19:27 PM
From: tuck  Read Replies (1) | Respond to of 897
 
This little item came out at noon ET, and allowed me to sell a few calls at my target price. I can't wait for the PIII exclusively for blacks and women.

>>Results from VaxGen Inc. (NasdaqNM:VXGN - News)'s latest trial don't discount earlier indications that the HIV vaccine might offer some protection to black people and women.

The company decided to diversify two years ago before it ran into difficulty with the HIV vaccine.

(An item published at 11:42 a.m. EST indicated the latest results dashed hopes that women and blacks might be aided by the vaccine and that difficultly with the vaccine prompted the company to diversify.) <<

Note the failure is also a slight negative for AGEN:

Message 18414753

Cheers, Tuck



To: tuck who wrote (604)11/12/2003 3:37:03 PM
From: keokalani'nui  Read Replies (1) | Respond to of 897
 
Yeah, but melanoma has responded to vaccine approach in other instances though not nearly well enough for fda approval.

Sorry, never even noticed there was a portfolio attached. I see it's in there. A big Duh! on my part.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News